1. Nash I. Chronic myeloid leukemia. N Engl J Med. 1999; 341:765. PMID:
10475801.
Article
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994–1004. PMID:
12637609.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344:1031–1037. PMID:
11287972.
Article
4. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99:1928–1937. PMID:
11877262.
Article
5. Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosurg Clin N Am. 2000; 11:399–406. PMID:
10918008.
Article
6. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2001; 87–112. PMID:
11722980.
Article
7. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008; 111:4022–4028. PMID:
18256322.
Article
8. Song KW, Rifkind J, Al-Beirouti B, et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma. 2004; 45:1633–1636. PMID:
15370217.
Article
9. Radaelli F, Vener C, Ripamonti F, et al. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol. 2007; 86:390–393. PMID:
18192104.
Article
10. Matsue K, Aoki T, Odawara J, Kimura S, Yamakura M, Takeuchi M. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Leuk Res. 2009; 33:867–869. PMID:
18951628.
11. Okajima K, Kohno I, Tsuruta J, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res. 1992; 66:717–727. PMID:
1519230.
Article
12. Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood. 1982; 59:1169–1180. PMID:
6177359.
Article
13. Favier R, Aoki N, de Moerloose P. Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol. 2001; 114:4–10. PMID:
11472338.
14. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009; 114:261–263. PMID:
19414863.
Article